CME Presentations

Carcinoid Syndrome



  • Jonathan R. Strosberg, MD

    Jonathan R. Strosberg, MD

    Jonathan R. Strosberg, MD

    Chair of the Gastrointestinal Department Research

    Jonathan R. Strosberg, MD, is an associate professor at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, specializing in gastrointestinal and neuroendocrine malignancies. He earned his medical degree from Cornell University Medical College and completed his residency at Georgetown University Hospital and fellowship at the H. Lee Moffitt Cancer Center. Dr Strosberg has published over 120 articles on diagnosing and managing neuroendocrine malignancies and is a recipient of the National Cancer Institute’s (NCI) Clinical Investigator Team Leadership Award. He serves on the board of directors of the North American Neuroendocrine Tumor Society, and on various committees of the NCI, National Comprehensive Cancer Network, and the American Joint Committee on Cancer.
  • Edward M. Wolin, MD

    Edward M. Wolin, MD

    Edward M. Wolin, MD

    Edward M. Wolin, MD, an internationally-renowned authority on neuroendocrine tumors, is the director of the Center for Carcinoid and Neuroendocrine Tumors and a professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai in New York. Dr Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy. He is co-medical director for the Carcinoid Cancer Foundation, is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research and is a reviewer for numerous journals, including the Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology.
  • Grace Goldstein

    Grace Goldstein

CME Information

Controlling Carcinoid Syndrome Symptoms: Best Practices in Diagnosis and Management

Mount Sinai Logo  


Upon completion of this activity, participants should be better able to:

  • Assess symptoms specific to carcinoid syndrome along with the impact of CS symptoms on patients’ QOL
  • Discuss the work-up of patients with carcinoid tumors who present with diarrhea
  • Adopt a multidisciplinary approach to diagnosing patients with DMD
  • Compare and contrast the mechanism of action, safety and efficacy of treatment options for CS symptoms
  • Determine the appropriate treatment to control CS symptoms

Activity Description and Educational Objectives

Carcinoid syndrome (CS) is associated with a heavy burden of symptoms and has substantial impacts on functioning and quality of life. However, it often goes unrecognized, untreated, and suboptimally managed. Clinicians require education that increases their ability to diagnose and evaluate this condition, and increases their knowledge, competence and confidence in using available medical therapies as well as monitoring and adjusting treatment to ensure optimal symptom relief for these patients. The 1-hour live, web-based CME activity will discuss the following: review the symptoms of CS, including available evidence from patient-reported outcomes studies and patient surveys; identify circumstances in which CS should be part of the differential diagnosis; review best practices for detecting and monitoring symptoms; and review the uses of currently available medical therapies for relieving symptoms. Effective clinician-patient communication strategies that contribute to these goals will be integrated and round off the discussion.


This activity is intended for US-based medical oncologists, endocrinologists, and advanced practitioners (nurse practitioners, physician assistants) who manage patients with neuroendocrine tumors (NETs). Clinicians in cardiology, dermatology, pulmonology, surgical oncology, radiation oncology, internal medicine, and primary care may also benefit from the education as they may encounter patients who present with signs and symptoms of CS.


There are no fees to participate in this activity. To participate in the activity, go to To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Live Activity
March 29, 2019 from 9:00am – 10:00am ET.

Enduring Material
Release Date: March 29, 2019
Expiration Date: March 29, 2020
Time to Complete Activity: 1 hour

Faculty & Disclosure / Conflict of Interest Policy

It is the policy of Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME–sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. The information will be available as part of the course material.

Course Director:
Edward Wolin, MD
Professor of Medicine (Hematology and Medical Oncology)
Icahn School of Medicine at Mount Sinai
New York, NY

Grace Goldstein, MA
Chief Operating Officer
Carcinoid Cancer Foundation

Peer Reviewer:
Jacqueline Carr, MD
Icahn School of Medicine at Mount Sinai
New York, NY

Faculty Presenter:
Jonathan R. Strosberg, MD
Associate Professor, Department of Oncologic Sciences, Section Head, Neuroendocrine Division, Chair of the Gastrointestinal Department Research
Moffitt Cancer Center
Tampa, FL

Course Director


Edward Wolin, MD Compensation for Time on Scientific Advisory Board: Advanced Accelerator Applications, Ipsen, Lexicon
Co-Director Disclosures
Grace Goldstein, MA Has nothing to disclose relevant to this activity.
Peer Reviewer Disclosures
Jacqueline Carr, MD Has nothing to disclose relevant to this activity.
Presenter Disclosures
Jonathan R. Strosberg, MD Consultant/Advisor, Research Support: Novartis
Honoraria for Lectures, Papers, Teaching: Ipsen, Lexicon
PlatformQ Health Education, LLC Disclosures
Joseph Chebli, PharmD Medical Director Stocks, Stock Options: Bristol-Myers Squibb
Elizabeth del Nido, Program Manager Has nothing to disclose relevant to this activity.


The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Icahn School of Medicine at Mount Sinai and PlatformQ Health Education. The Icahn School of Medicine at Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

The Icahn School of Medicine at Mount Sinai designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits ™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.


This activity is supported by an educational grant from Lexicon Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of the Icahn School of Medicine at Mount Sinai any of its partners, providers, and/or supporters.


This activity consists of one session which should take approximately 1 hour to complete.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

Privacy and Confidentiality Policy

The Icahn School of Medicine protects the privacy of personal and other information regarding participants and educational collaborations. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.


Contact Information:
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity at

Copyright -
This material is protected by copyright and other intellectual property laws. It may not be otherwise copied, printed, transmitted, or published unless explicit permission is obtained. To request permission, please contact us at

Technical Support
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at